What is the recommended initial dose of Falcigo (artesunate) for treatment?

Falcigo First Dose for Severe Malaria

For severe malaria (all species), the first dose of intravenous artesunate is 2.4 mg/kg body weight, administered at time 0, followed by repeat doses at 12 hours and 24 hours. 1

Dosing Algorithm for Artesunate (Falcigo)

Severe/Complicated Malaria (First-Line Treatment)

• Initial dose: 2.4 mg/kg IV at time 0
• Second dose: 2.4 mg/kg IV at 12 hours
• Third dose: 2.4 mg/kg IV at 24 hours
• Continuation: 2.4 mg/kg IV daily for up to 7 days if:
  • Patient unable to take oral medication, OR
  • Parasitemia >1%
• Transition to oral therapy: Switch to full course of oral ACT (artemisinin-based combination therapy) once:
  • Patient can tolerate oral medication, AND
  • Parasitemia <1%
  • Do not switch before completing at least 48 hours of IV treatment 1

Critical Monitoring Parameters

• Parasitemia checks: Every 12 hours until decline to <1%, then every 24 hours until negative 1
• Laboratory monitoring: Daily complete blood count, hepatic function, renal function, glucose, and blood gas analysis 1
• Post-treatment surveillance: Monitor for delayed hemolysis on days 7,14,21, and 28 (post-artesunate delayed hemolysis/PADH is a known complication) 1

Important Clinical Considerations

Artesunate formulation: The standard vial contains 110 mg artesunate for IV administration 1

Weight-based dosing is critical: Incorrect dosing has been associated with unfavorable hospital outcomes and increased mortality 2. Calculate the exact dose based on patient weight—do not estimate.

Rapid parasite clearance: Artesunate achieves parasite elimination typically within 36-41 hours, significantly faster than quinine (82 hours) 1, 3. This rapid action is crucial for preventing progression to vital organ dysfunction.

Common Pitfalls to Avoid

1. Delaying the 12-hour dose: Strict adherence to the 0,12, and 24-hour schedule is essential—compliance with this timing improves outcomes 2
2. Premature switch to oral therapy: Complete at least 48 hours of IV treatment before transitioning, even if patient appears improved 1
3. Missing post-treatment hemolysis monitoring: PADH can occur weeks after treatment completion and requires scheduled follow-up 1

Alternative if artesunate unavailable: Quinine dihydrochloride 20 mg salt/kg IV over 4 hours (loading dose), then 10 mg/kg over 4 hours every 8 hours, but this is inferior to artesunate for preventing red blood cell sequestration 1